Last reviewed · How we verify

discomfort — Treatment Landscape & Competitive Intelligence

discomfort (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating discomfort, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Hemorrhoid, Fissure, ProctalgiaSuppositories BORNEOL WU XI ZHONG ZHI WEI NA TECHNOLOGY CO., Ltd. Non-Standardized Chemical Allergen [EPC]
Influenza Influenza and COVID-19 Combination A BioNTech Non-Standardized Plant Allergenic Extract [EPC] SARS-CoV-2 spike protein and influenza hemagglutinin protein
Influenza Influenza and COVID-19 Combination B BioNTech Non-Standardized Plant Allergenic Extract [EPC] Not specified

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. BioNTech · 2 drugs in discomfort
  2. WU XI ZHONG ZHI WEI NA TECHNOLOGY CO., Ltd. · 1 drug in discomfort

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in discomfort:

Cite this brief

Drug Landscape (2026). discomfort — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/discomfort. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing